G. Srkalović

发表

Proteasome inhibitors: new class of antitumor agents.

G. Srkalović, 2003, Bosnian journal of basic medical sciences.

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Robert B Livingston, Gordan Srkalovic, Brian Leyland-Jones, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.

T. Kelley, S. Alkan, G. Srkalović, 2004, Leukemia research.

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

G. Sica, T. Owonikoko, S. Ramalingam, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.

Matthew J. Frigault, B. Alexander, S. Wander, 2021, Acta medica academica.

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.

T. Choueiri, G. Srkalović, J. Zeldis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Relative dose intensity of systemic chemotherapy in an outpatient cancer center

G. Srkalović, Claire E. Saadeh, Christine E. Uptigrove, 2010 .

Chemotherapy interruptions in relation to symptom severity in advanced breast cancer

G. Srkalović, A. Sikorskii, David E Victorson, 2015, Supportive Care in Cancer.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

V. Devanarayan, K. Pittman, T. Owonikoko, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center.

G. Srkalović, Christine E. Uptigrove, Kari L. Vavra, 2013, Journal of oncology practice.

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

E. Winer, B. Leyland-Jones, R. Livingston, 2013 .

Evaluation of receptors for somatostatin in various tumors using different analogs.

A. Schally, G. Srkalović, R. Cai, 1990, The Journal of clinical endocrinology and metabolism.

Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.

E. Jenison, A. Schally, G. Srkalović, 1998, International journal of oncology.

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

R. Bukowski, G. Srkalović, P. Elson, 2002, Cancer.

Bortezomib in recurrent and/or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

J. Rossi, E. Jaffe, N. Munshi, 2018, Blood.

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry

A. Bagg, M. Lim, G. Srkalović, 2022, British journal of haematology.

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

É. Oksenhendler, A. Bagg, M. Lim, 2020, American journal of hematology.

Special Report International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

J. Rossi, E. Jaffe, N. Munshi, 2019 .

TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.

I. Marijanović, G. Srkalović, D. Fajgenbaum, 2017, Bosnian journal of basic medical sciences.

ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder

E. Jaffe, É. Oksenhendler, K. Elenitoba-Johnson, 2020, Cell reports. Medicine.

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

N. Munshi, É. Oksenhendler, K. Elenitoba-Johnson, 2020, Blood advances.

Castleman disease spectrum.

E. Jaffe, M. Lim, G. Srkalović, 2020 .

Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:

B. Barlogie, S. Jagannath, S. Singhal, 2006, Cancer.

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

D. Esseltine, B. Barlogie, S. Jagannath, 2006, Haematologica.

Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.

A. Schally, G. Srkalović, V. Csernus, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Receptors for d-Trp6-Luteinizing Hormone-Releasing Hormone, Somatostatin, and Insulin-Like Growth Factor I in MXT Mouse Mammary Carcinoma

B. Szende, A. Schally, K. Groot, 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin

B. Szende, A. Schally, G. Srkalović, 1989, Breast Cancer Research and Treatment.

Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.

A. Schally, S. Radulović, G. Srkalović, 1990, Endocrinology.

Inhibitory effects of analogs of luteinizing hormone‐releasing hormone and somatostatin on pancreatic cancers in hamsters events that accompany tumor regression

B. Szende, A. Schally, K. Groot, 1990, Cancer.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.

Liang Li, Gordan Srkalovic, G. Srkalović, 2005, Mayo Clinic proceedings.

Tryptophan Loading Modulates Light-Induced Responses in the Mammalian Circadian System

G. Srkalović, J. Glass, M. A. Rea, 1995, Journal of biological rhythms.

Serotonergic inhibition of extracellular glutamate in the suprachiasmatic nuclear region assessed using in vivo brain microdialysis

G. Srkalović, J. Glass, M. A. Rea, 1994, Brain Research.

Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).

A. Schally, K. Szepesházi, G. Srkalović, 1991, Neuroendocrinology.

Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.

A. Schally, G. Srkalović, J. Wittliff, 1990, Cancer research.

Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)

O. Frankfurt, M. Tallman, N. Callander, 2019, Acta Haematologica.

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.

G. Srkalović, W. Audeh, L. Blumencranz, 2019, Acta medica academica.

Lung Cancer: Preventable Disease.

G. Srkalović, 2018, Acta medica academica.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital.

G. Srkalović, J. Herman, Harsha Trivedi, 2019, Acta medica academica.

Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells.

J. Tímár, B. Szende, A. Schally, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

Gordan Srkalovic, G. Srkalović, L. Rybicki, 2004, Cancer.

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

J. Rossi, E. Jaffe, É. Oksenhendler, 2017, Blood.

Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.

B. Szende, A. Schally, K. Groot, 1990, Cancer research.

Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.

B. Szende, A. Schally, K. Groot, 1990, Journal of the National Cancer Institute.

Antitumor effects of analogs of LH-RH and somatostatin: Experimental and clinical studies

B. Szende, A. Schally, K. Groot, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

ADVERSE EFFECT OF TAMOXIFEN WITH LHRH AGONIST ON OESTROGEN-RECEPTOR-NEGATIVE MAMMARY CARCINOMA

B. Szende, A. Schally, G. Srkalović, 1989, The Lancet.

Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.

Gordan Srkalovic, Esteban Walker, Eric Hsi, 2006, Mayo Clinic proceedings.

Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma

G. Srkalović, M. Kalaycio, J. Zeldis, 2014, American journal of hematology.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia

A. Schally, G. Srkalović, T. Redding, 1989, The Prostate.

Management of multiple myeloma in the era of novel drugs.

G. Srkalović, Ines Srkalovic, 2010 .

Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.

G. Srkalović, M. Hussein, 2009, Bosnian journal of basic medical sciences.

Role of Apo2L/TRAIL and Bcl-2-family Proteins in Apoptosis of Multiple Myeloma

S. Ray, A. Almasan, G. Srkalović, 2003, Leukemia & lymphoma.

Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02).

R. Fonseca, M. Gertz, P. Greipp, 2007 .

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

B. Barlogie, R. Orlowski, G. Srkalović, 2014, Cancer medicine.

Acquired activated protein C resistance in myeloma patients with venous thromboembolic events.

T. Choueiri, G. Srkalović, S. Deitcher, 2003, British journal of haematology.

Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).

A. Schally, K. Groot, G. Srkalović, 2009, International journal of peptide and protein research.

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis

Gordan Srkalovic, G. Srkalović, Marte G Cameron, 2005, International seminars in surgical oncology : ISSO.

Prognostic factors of overall survival for patients with stage II colon cancer.

G. Srkalović, J. Herman, Harsha Trivedi, 2014, Acta medica academica.

Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

A. Juhász, G. Srkalović, Z. Rékási, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.

A. Juhász, G. Srkalović, V. Csernus, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Mycobacterium avium Complex Infection After Alemtuzumab Therapy for Chronic Lymphocytic Leukemia

G. Srkalović, Claire Saadeh, 2008, Pharmacotherapy.

MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)

James X. Sun, P. Stephens, S. Ou, 2017 .

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

G. Srkalović, W. Audeh, H. Soliman, 2020, BMC Cancer.

Acute Hypersensitivity Reaction to Ferric Gluconate in a Premedicated Patient

G. Srkalović, Claire Saadeh, 2005, The Annals of pharmacotherapy.

The effect of calcium-channel-blocking agents on the various types of smooth muscle activation of the isolated rat uterus.

G. Srkalović, V. Varagić, S. Milovanovic, 1984, Archives internationales de pharmacodynamie et de therapie.

Cyclin D1 positive follicular lymphoma

G. Srkalović, E. McPhail, M. Hall, 2009, Journal of Clinical Pathology.

Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease

A. Bagg, M. Lim, G. Srkalović, 2021, Blood.

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

G. Srkalović, P. Elson, M. Hussein, 2002, Medical oncology.

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

A. Bagg, M. Lim, G. Srkalović, 2022, Blood.

Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

A. Schally, G. Srkalović, V. Csernus, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Changing Landscape of Clinical-Genomic Oncology Practice.

Harsha Trivedi, Heather M Kling, Tina Treece, 2019, Acta medica academica.

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

D. Cella, T. Owonikoko, S. Ramalingam, 2020, Cancer medicine.

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

G. Srkalović, W. Audeh, H. Soliman, 2020, BMC Cancer.

Genomics in Hematology and Oncology Practice.

G. Srkalović, 2019, Acta medica academica.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

V. Devanarayan, K. Pittman, T. Owonikoko, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

G. Srkalović, J. Zeldis, G. Pearce, 2004 .

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC.

K. Pittman, T. Owonikoko, S. Ramalingam, 2012 .